A new series of estrogen receptor modulators that display selectivity for estrogen receptor β

被引:148
作者
Henke, BR
Consler, TG
Go, N
Hale, RL
Hohman, DR
Jones, SA
Lu, AT
Moore, LB
Moore, JT
Orband-Miller, LA
Robinett, RG
Shearin, J
Spearing, PK
Stewart, EL
Turnbull, PS
Weaver, SL
Williams, SP
Wisely, GB
Lambert, MH
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] Affymax Res Inst, Santa Clara, CA 95051 USA
关键词
D O I
10.1021/jm020291h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 1,3,5-triazine-based estrogen receptor (ER) modulators that are modestly selective for the ERbeta subtype are reported. Compound 1, which displayed modest potency and selectivity for ERbeta vs ERalpha, was identified via high-throughput screening utilizing an ERbeta SPA-based binding assay. Subsequent analogue preparation resulted in the identification of compounds such as 21 and 43 that display 25- to 30-fold selectivity for ERbeta with potencies in the 10-30 nM range. These compounds profile as full antagonists at ERbeta and weak partial agonists at ERalpha in a cell-based reporter gene assay. In addition, the X-ray crystal structure of compound 15 complexed with the ligand binding domain of ERbeta has been solved and was utilized in the design of more conformationally restrained analogues such as 31 in an attempt to increase selectivity for the ERbeta subtype.
引用
收藏
页码:5492 / 5505
页数:14
相关论文
共 52 条
[1]   The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site [J].
Anstead, GM ;
Carlson, KE ;
Katzenellenbogen, JA .
STEROIDS, 1997, 62 (03) :268-303
[2]   Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists [J].
Barkhem, T ;
Carlsson, B ;
Nilsson, Y ;
Enmark, E ;
Gustafsson, JÅ ;
Nilsson, S .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :105-112
[3]   The potential of SERMs for reducing the risk of coronary heart disease [J].
Barrett-Connor, E ;
Cox, DA ;
Anderson, PW .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1999, 10 (08) :320-325
[4]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[5]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[6]   Selective estrogen receptor modulators: Clinical spectrum [J].
Cosman, F ;
Lindsay, R .
ENDOCRINE REVIEWS, 1999, 20 (03) :418-434
[7]   Estrogen receptor null mice: What have we learned and where will they lead us? [J].
Couse, JF ;
Korach, KS .
ENDOCRINE REVIEWS, 1999, 20 (03) :358-417
[8]  
Dupont S, 2000, DEVELOPMENT, V127, P4277
[9]   Different ligands-different receptor conformations:: Modeling of the hERα LBD in complex with agonists and antagonists [J].
Egner, U ;
Heinrich, N ;
Ruff, M ;
Gangloff, M ;
Mueller-Fahrnow, A ;
Wurtz, JM .
MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) :523-539
[10]   Potent estrogen agonists based on carborane as a hydrophobic skeletal structure - A new medicinal application of boron clusters [J].
Endo, Y ;
Iijima, T ;
Yamakoshi, Y ;
Fukasawa, H ;
Miyaura, C ;
Inada, M ;
Kubo, A ;
Itai, A .
CHEMISTRY & BIOLOGY, 2001, 8 (04) :341-355